Motus GI Holdings Net Income 2011-2026 | MOTS

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.^[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income Motus GI Holdings

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-12.9 M	-18.6 M	-19 M	-19.3 M	-23.1 M	-22.3 M	-13.2 M	-8.02 M	-5.99 M	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-5.99 M	-23.1 M	-15.8 M

Quarterly Net Income Motus GI Holdings

2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-2.11 M	-	-2.68 M	-3 M	-4.39 M	-	-4.96 M	-5.14 M	-4.81 M	-	-4.82 M	-4.74 M	-4.65 M	-	-3.94 M	-4.41 M	-6.51 M	-	-5.2 M	-5.68 M	-6.27 M	-	-5.17 M	-4.2 M	-7.32 M	-	-3.16 M	-3.48 M	-2.78 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-2.11 M	-7.32 M	-4.52 M

References

Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Diagnostics research industry

Issuer	Net Income	Price	% 24h	Market Cap	Country
Centogene N.V. CNTG	-46.9 M	-	-6.23 %	$ 30.6 M	Germany
Burning Rock Biotech Limited BNR	-797 M	$ 18.56	10.74 %	$ 196 M	China
Agilent Technologies A	1.21 B	-	-	$ 34.4 B	USA
Castle Biosciences CSTL	-24.2 M	$ 18.88	4.02 %	$ 547 M	USA
Fulgent Genetics FLGT	-42.7 M	$ 16.19	1.44 %	$ 490 M	USA
Akumin AKU	-157 M	-	-17.87 %	$ 25.9 M	Canada
Interpace Biosciences IDXG	24.6 M	$ 1.8	-5.26 %	$ 7.96 M	USA
Aspira Women's Health AWH	-12.8 M	-	-6.19 %	$ 10.5 M	USA
Accelerate Diagnostics AXDX	-14.6 M	-	-61.36 %	$ 2.46 M	USA
Biocept BIOC	-32.1 M	-	-13.05 %	$ 7.29 M	USA
Oxford Immunotec Global PLC OXFD	-1.81 M	-	-	$ 562 M	Britain
CareDx, Inc CDNA	-21.4 M	$ 20.49	-0.58 %	$ 1.09 B	USA
Chembio Diagnostics CEMI	-23.3 M	-	0.22 %	$ 16.8 M	USA
Medpace Holdings MEDP	451 M	$ 419.17	-1.08 %	$ 12.1 B	USA
Check-Cap Ltd. CHEK	4.14 M	-	-	$ 9.42 M	Israel
Lantheus Holdings LNTH	234 M	-	-	$ 6.5 B	USA
Mettler-Toledo International MTD	869 M	$ 1 041.91	1.75 %	$ 21.5 B	Schweiz
Myriad Genetics MYGN	-366 M	$ 3.62	-2.95 %	$ 335 M	USA
HTG Molecular Diagnostics HTGM	-21.6 M	-	-20.0 %	$ 1.06 M	USA
Co-Diagnostics CODX	-46.9 M	$ 1.63	1.87 %	$ 2.17 M	USA
NeoGenomics NEO	-108 M	$ 8.36	1.21 %	$ 1.07 B	USA
National Research Corporation NRC	11.6 M	$ 18.93	1.39 %	$ 424 M	USA
Natera NTRA	-548 M	$ 196.91	0.81 %	$ 19.4 B	USA
Global Cord Blood Corporation CO	501 M	-	-	$ 399 M	China
Fluidigm Corporation FLDM	-53 M	-	1.08 %	$ 308 M	USA
Genetic Technologies Limited GENE	-7.13 M	-	-	$ 7.1 B	Australia
Genetron Holdings Limited GTH	-503 M	-	0.12 %	$ 80.1 M	China
DermTech DMTK	-101 M	-	-11.32 %	$ 2.94 M	USA
Charles River Laboratories International CRL	-144 M	$ 159.12	-2.29 %	$ 7.89 B	USA
PRA Health Sciences, Inc. PRAH	197 M	-	-	$ 10.7 B	USA
Koninklijke Philips N.V. PHG	897 M	$ 25.5	-0.51 %	$ 24.2 B	Niderland
Enzo Biochem ENZ	-26.1 M	-	-8.98 %	$ 14.8 K	USA
Exact Sciences Corporation EXAS	-208 M	-	-	$ 19.8 B	USA
Personalis PSNL	-81.3 M	$ 6.71	5.01 %	$ 599 M	USA
Guardant Health GH	-416 M	$ 98.66	0.19 %	$ 12.4 B	USA
Senseonics Holdings SENS	-69.1 M	$ 5.82	5.82 %	$ 243 M	USA
Heska Corporation HSKA	-19.9 M	-	-	$ 1.31 B	USA
ICON Public Limited Company ICLR	791 M	$ 117.09	-0.25 %	$ 9.66 B	Irlanda
Illumina ILMN	-1.22 B	$ 143.24	-1.21 %	$ 22.8 B	USA
Soleno Therapeutics SLNO	20.9 M	$ 52.99	0.08 %	$ 2.69 B	USA
Trinity Biotech plc TRIB	-31.2 M	$ 0.58	-1.08 %	$ 208 M	Irlanda
QIAGEN N.V. QGEN	425 M	-	-	$ 10.6 B	Niderland
Twist Bioscience Corporation TWST	-77.7 M	$ 52.95	-2.65 %	$ 3.17 B	USA
Biomerica BMRA	-4.97 M	$ 2.41	7.11 %	$ 5.54 M	USA
Thermo Fisher Scientific TMO	6.7 B	$ 448.21	0.49 %	$ 169 B	USA
Laboratory Corporation of America Holdings LH	876 M	$ 254.02	-0.16 %	$ 21.1 B	USA
Waters Corporation WAT	643 M	$ 333.21	-0.51 %	$ 19.8 B	USA
Celcuity CELC	-177 M	$ 134.72	8.23 %	$ 6.3 B	USA
Neogen Corporation NEOG	-1.09 B	$ 8.43	-2.99 %	$ 1.83 B	USA